Healthy Active AthletesNCT07714057
Effect of Hydrogen-rich Water During Tapering on Recovery After Functional Overreaching in Basketball Players
A study testing Hydrogen-rich water in people with Healthy Active Athletes, run by Palacky University at 1 site in Czechia.
Trial summary
The goal of this clinical trial is to evaluate whether hydrogen-rich water supplementation during tapering improves recovery after functional overreaching in competitive male basketball players aged 18-35 years. Read more about this study
- Who is it for?
- Ages 18 to 35 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy Active Athletes
- What is being tested?
- Hydrogen-rich water
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 30 participants
- Where
- 1 siteCzechia
- Study dates
- 27 Jul 2026to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Competitive male basketball players.
- Signed informed consent.
- Completion of entry medical and laboratory screening.
Who cannot join
- Acute injury or infection.
- History or presence of relevant cardiovascular, respiratory, metabolic, or other disease that may affect the study results.
- Use of medication affecting recovery markers or study results.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Jakub Krejci, PhD contact
Czechia1 site, 1 recruiting
- Recruiting
Palacky University, Faculty of Physical Culture
Olomouc, 77111
Jan Kvas, +420774678756, jan.kvas01@upol.cz
About this study
Official title: Effect of Hydrogen-rich Water Supplementation During Tapering on Recovery After Functional Overreaching in Competitive Male Basketball Players: A Randomized, Double-blind, Placebo-controlled Paralel-group Trial
The goal of this clinical trial is to evaluate whether hydrogen-rich water supplementation during tapering improves recovery after functional overreaching in competitive male basketball players aged 18-35 years. The main questions it aims to answer are:
- Does hydrogen-rich water improve autonomic recovery after functional overreaching?
- Does hydrogen-rich water improve recovery in biochemical, performance, and subjective feeling outcomes during tapering?
Read more
Researchers will compare hydrogen-rich water to placebo (water containing no molecular hydrogen) to determine whether molecular hydrogen improves recovery after accumulated fatigue has been induced by functional overreaching. Participants will:
- Complete a training cycle including normal training, functional overreaching, and tapering.
- Consume hydrogen-rich or placebo water daily during the one-week tapering period.
- Undergo repeated testing of autonomic nervous system, blood biochemical markers, performance, and subjective soreness.
Read the detailed description
The study consists of an initial screening and entry testing phase, followed by one week of normal training, two weeks of functional overreaching, and one week of tapering. During the functional overreaching period, training load is increased to approximately 120-130% of normal training load to induce accumulated fatigue. During the tapering period, training volume is reduced to approximately 50-60% of normal training volume to support recovery and performance rebound.
The molecular hydrogen is administered only during the tapering period. Participants in the experimental group consume 2.5 L per day of hydrogen-rich water. The total daily dose is divided into 0.5 L in the morning, 1.5 L around training, and 0.5 L in the evening. Participants in the placebo group consume visually matched placebo water according to the same total daily intake and timing schedule. Supplementation adherence is monitored using logs, dose counts, and attendance records. Participants are randomly assigned in a 1:1 ratio to either the experimental group or the placebo group. Randomization is performed using a block scheme and a computer random number generator.
Testing is performed at multiple time points: entry laboratory testing, baseline after normal training, post-functional overreaching, and post-taper. The primary interval for evaluation is the change from post-functional overreaching to post-taper. Statistical analysis is based on a t-test or analysis of variance. Data that not follow a normal distribution are treated using a logarithmic transformation or analyzed using nonparametric tests. The significance level is set at 0.05.
- Conditions
- Healthy Active Athletes
- Being tested
- Hydrogen-rich water, Placebo water
- Keywords
- molecular hydrogen, functional overreaching, tapering, heart rate variability, basketball
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Hydrogen-rich waterDietary supplement
Also called Tirtan generator (Nutristamina, Ostrava, Czech Republic)
Hydrogen-rich water with molecular hydrogen concentration >1.0 ppm.
Placebo waterDietary supplement
Tap water without molecular hydrogen.
| Study group | Role | What they receive |
|---|---|---|
| Hydrogen-rich water | Experimental | Hydrogen-rich water administered at a dose of 2.5 L per day during a one-week tapering period. Receives: Dietary Supplement: Hydrogen-rich water |
| Placebo water | Placebo comparator | Placebo water administered at a dose of 2.5 L per day during a one-week tapering period. Receives: Dietary Supplement: Placebo water |
What is being measured
The primary outcome is the main question the study is designed to answer.
RMSSD
The root mean square of successive differences of RR intervals (RMSSD) is used as an index of parasympathetic activity and is calculated from an ECG using heart rate variability analysis.
Measured: One-week change between post-overreaching and post-taper.
Secondary outcomes (15)
Creatine kinase
Blood creatine kinase concentration is used as a marker of muscle damage.
Measured: One-week change between post-overreaching and post-taper.
High-sensitivity C-reactive protein
High-sensitivity C-reactive protein concentration is used as a marker of systemic inflammatory.
Measured: One-week change between post-overreaching and post-taper.
Cortisol
Blood cortisol concentration is used as a marker of physiological stress response.
Measured: One-week change between post-overreaching and post-taper.
Testosterone
Blood testosterone concentration is used as a marker related to anabolic-catabolic balance.
Measured: One-week change between post-overreaching and post-taper.
Urea
Blood urea concentration is used as a marker related to metabolic and protein-turnover stress.
Measured: One-week change between post-overreaching and post-taper.
Leukocytes
Blood leukocyte count is used as a marker of immune-related response to training.
Measured: One-week change between post-overreaching and post-taper.
Lymphocytes
Blood lymphocyte count is used as a marker of immune-related response to training.
Measured: One-week change between post-overreaching and post-taper.
Neutrophils
Blood lymphocyte count is used as a marker of imflammatory response to training.
Measured: One-week change between post-overreaching and post-taper.
Reactive strength index
Reactive strength index is used as an marker of neuromuscular function of the lower limbs and is measured using a drop jump.
Measured: One-week change between post-overreaching and post-taper.
Hangrip test
Handgrip test is used as a marker of forearm muscle strength and is measured using a dynamometer.
Measured: One-week change between post-overreaching and post-taper.
20-m sprint
20-m sprint test is used to assess linear speed.
Measured: One-week change between post-overreaching and post-taper.
Repeated sprint
20 x 15 m repeated sprint test is used to asses repeated sprint ability.
Measured: One-week change between post-overreaching and post-taper.
Agility T-test
Agility T-test is used to assess planned change-of-direction performance.
Measured: One-week change between post-overreaching and post-taper.
Basketball jump shot accuracy test
Basketball jump shot accuracy test is used to assess basketball-specific performance.
Measured: One-week change between post-overreaching and post-taper.
Muscle soreness
Muscle soreness is assessed subjectively using a visual analog scale, which is represented by a 100 mm line marked 0 (no pain) and 100 (worst imaginable pain).
Measured: One-week change between post-overreaching and post-taper.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jul 2026
- Study start27 Jul 2026
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy Active AthletesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Palacky University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jakub Krejci, Palacky University
- Investigators
- Jan Kvas, Principal investigator, Palacky University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07714057
- Sponsor's protocol ID
- FTK_2026_13
- Status last verified
- Jul 2026
- First submitted
- 15 Jul 2026
- Last updated
- 28 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All IPD that underlie results in a publication.
Study at a glance
From the registry record, last updated by the sponsor on 28 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Hydrogen-rich Water Supplementation During Tapering on Recovery After Functional Overreaching in Competitive Male Basketball Players: A Randomized, Double-blind, Placebo-controlled Paralel-group Trial
- ClinicalTrials.gov ID
- NCT07714057
- Acronym / sponsor ID
- FTK_2026_13
- Conditions
- Healthy Active Athletes
- Keywords
- molecular hydrogen, functional overreaching, tapering, heart rate variability, basketball
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Palacky UniversityUniversity, hospital or other
- Study start
- 27 Jul 2026 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 20 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate whether hydrogen-rich water supplementation during tapering improves recovery after functional overreaching in competitive male basketball players aged 18-35 years. The main questions it aims to answer are:
- Does hydrogen-rich water improve autonomic recovery after functional overreaching?
- Does hydrogen-rich water improve recovery in biochemical, performance, and subjective feeling outcomes during tapering?
Researchers will compare hydrogen-rich water to placebo (water containing no molecular hydrogen) to determine whether molecular hydrogen improves recovery after accumulated fatigue has been induced by functional overreaching. Participants will:
- Complete a training cycle including normal training, functional overreaching, and tapering.
- Consume hydrogen-rich or placebo water daily during the one-week tapering period.
- Undergo repeated testing of autonomic nervous system, blood biochemical markers, performance, and subjective soreness.
Detailed description
The study consists of an initial screening and entry testing phase, followed by one week of normal training, two weeks of functional overreaching, and one week of tapering. During the functional overreaching period, training load is increased to approximately 120-130% of normal training load to induce accumulated fatigue. During the tapering period, training volume is reduced to approximately 50-60% of normal training volume to support recovery and performance rebound.
The molecular hydrogen is administered only during the tapering period. Participants in the experimental group consume 2.5 L per day of hydrogen-rich water. The total daily dose is divided into 0.5 L in the morning, 1.5 L around training, and 0.5 L in the evening. Participants in the placebo group consume visually matched placebo water according to the same total daily intake and timing schedule. Supplementation adherence is monitored using logs, dose counts, and attendance records. Participants are randomly assigned in a 1:1 ratio to either the experimental group or the placebo group. Randomization is performed using a block scheme and a computer random number generator.
Testing is performed at multiple time points: entry laboratory testing, baseline after normal training, post-functional overreaching, and post-taper. The primary interval for evaluation is the change from post-functional overreaching to post-taper. Statistical analysis is based on a t-test or analysis of variance. Data that not follow a normal distribution are treated using a logarithmic transformation or analyzed using nonparametric tests. The significance level is set at 0.05.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Hydrogen-rich water | Experimental | Dietary Supplement: Hydrogen-rich waterHydrogen-rich water administered at a dose of 2.5 L per day during a one-week tapering period. |
| Placebo water | Placebo comparator | Dietary Supplement: Placebo waterPlacebo water administered at a dose of 2.5 L per day during a one-week tapering period. |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Competitive male basketball players.
- Signed informed consent.
- Completion of entry medical and laboratory screening.
Key exclusion criteria (3 listed)
- Acute injury or infection.
- History or presence of relevant cardiovascular, respiratory, metabolic, or other disease that may affect the study results.
- Use of medication affecting recovery markers or study results.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Hydrogen-rich waterAlso: Tirtan generator (Nutristamina, Ostrava, Czech Republic)Hydrogen-rich water with molecular hydrogen concentration >1.0 ppm. | Dietary supplement | Hydrogen-rich water |
| Placebo waterTap water without molecular hydrogen. | Dietary supplement | Placebo water |
Primary outcome
RMSSD
Time frame: One-week change between post-overreaching and post-taper.
The root mean square of successive differences of RR intervals (RMSSD) is used as an index of parasympathetic activity and is calculated from an ECG using heart rate variability analysis.
15 secondary outcomes
Creatine kinase
Time frame: One-week change between post-overreaching and post-taper.
High-sensitivity C-reactive protein
Time frame: One-week change between post-overreaching and post-taper.
Cortisol
Time frame: One-week change between post-overreaching and post-taper.
Testosterone
Time frame: One-week change between post-overreaching and post-taper.
Urea
Time frame: One-week change between post-overreaching and post-taper.
Leukocytes
Time frame: One-week change between post-overreaching and post-taper.
Lymphocytes
Time frame: One-week change between post-overreaching and post-taper.
Neutrophils
Time frame: One-week change between post-overreaching and post-taper.
Reactive strength index
Time frame: One-week change between post-overreaching and post-taper.
Hangrip test
Time frame: One-week change between post-overreaching and post-taper.
20-m sprint
Time frame: One-week change between post-overreaching and post-taper.
Repeated sprint
Time frame: One-week change between post-overreaching and post-taper.
Agility T-test
Time frame: One-week change between post-overreaching and post-taper.
Basketball jump shot accuracy test
Time frame: One-week change between post-overreaching and post-taper.
Muscle soreness
Time frame: One-week change between post-overreaching and post-taper.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jul 2026.
- Individual participant dataSharing planned: Yes. All IPD that underlie results in a publication.
Related trials for Healthy Active Athletes
Recruiting
Effect of a Fermented Dairy Protein With Prebiotic Fiber on GI Complaints
Digestive Health, Quality of Life
Recruiting
Endurance Trial: Ketone and Carbohydrate Supplementation
Athletic Performance, Exercise
Recruiting
Effects of Exercise Timing on Sleep Quality
Healthy Endurance Athlet, Inactive People
Recruiting
Intermittent Hypoxic Training (IHT) Versus Hyperbaric Oxygen Therapy (HBOT) for Aerobic Performance
Healthy Active Athletes
Not yet recruitingObservational study
Menstrual Cycle and Women's Performance
Menstrual Cycle, Physical Performance
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jakub Krejci, PhD contact
Jan Kvas principal investigator
Palacky University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Hydrogen-rich water in people with Healthy Active Athletes, run by Palacky University at 1 site in Czechia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Czechia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jan Kvas (+420774678756, jan.kvas01@upol.cz), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
RMSSD (time frame: One-week change between post-overreaching and post-taper.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jul 2026.